Amylyx Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Amylyx Pharmaceuticals, Inc. (AMLX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $8.32 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $8.32M, a 13.17% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $6.12M, a 10.43% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $7.08M, a 4.01% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $7.35M, a 23.20% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $27.64M, a 16.32% decline from fiscal 2024.
- Amylyx Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $33.04M, a 12.01% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $37.55M, a 72.91% increase from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $21.71M, a 592.41% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.32M 10-Q · filed 2026-08-06 | $14.44M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $6.12M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $27.64M 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $7.08M 10-Q · filed 2025-11-06 | $14.43M derived: sum of 2 quarters · filed 2026-08-06 | $21.26M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $7.35M 10-Q · filed 2026-08-06 | $14.18M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $6.83M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $33.04M 10-K · filed 2026-03-03 | |||
| 2024-09-30 | $6.80M 10-Q · filed 2025-11-06 | $16.37M derived: sum of 2 quarters · filed 2025-11-06 | $26.30M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $9.57M 10-Q · filed 2025-11-06 | $19.49M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $9.92M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $37.55M 10-K · filed 2025-03-04 | |||
| 2023-09-30 | $10.28M 10-Q · filed 2024-11-07 | $20.34M derived: sum of 2 quarters · filed 2024-11-07 | $27.92M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $10.05M 10-Q · filed 2024-11-07 | $17.63M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $7.58M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $21.71M 10-K · filed 2024-02-22 | |||
| 2022-09-30 | $5.52M 10-Q · filed 2023-11-09 | $11.23M derived: sum of 2 quarters · filed 2023-11-09 | $15.62M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $5.71M 10-Q · filed 2023-11-09 | $10.10M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $4.39M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $3.14M 10-K · filed 2024-02-22 | |||
| 2021-09-30 | $802.00K 10-Q · filed 2022-11-10 | $1.46M derived: sum of 2 quarters · filed 2022-11-10 | $2.04M derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $657.00K 10-Q · filed 2022-11-10 | $1.24M derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $586.00K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |